n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, December 29th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Bravada Gold Corp. (BGAVF)

Real Pennies and Gold Investment Letter reported previously on Bravada Gold Corp. (BGAVF), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Bravada Gold Corp. is a Nevada-focused exploration and development company. The Company has a large portfolio of high-quality properties. These properties cover a range of development stages - from early-stage exploration to advanced-stage exploration and pre-development. Listed on the OTC Markets Group’s OTCQB, Bravada Gold has its head office in Vancouver, British Columbia.

Bravada Gold explores for precious metals in well-established gold trends in one of the world's best gold jurisdictions. Currently, five of its Nevada properties are being funded by partners. In total this includes earn-in work expenditures of up to $6.5 million and payments to Bravada Gold of up to +$3.0 million in cash and shares.

Bravada Gold retains residual working or royalty interests.
For 2017, the Company says that mine permitting continues on its Shoshone Pediment project. Bravada holds a royalty on eventual barite production.

Pertaining to its Wind Mountain project, Bravada Gold’s plan is to drill-test for high-grade “Hishikari-type” gold/silver vein mineralization beneath the existing disseminated resource at Wind Mountain. Regarding the SF property, the Company plans to drill-test for high-grade “Carlin-type” gold mineralization at the SF property.

Concerning the North Lone Mountain and South Lone Mountain projects, plans have not been finalized for Bravada’s two claim groups. However, Nevada Zinc continues to expand the footprint of zinc mineralization on its claims towards Bravada’s South Lone Mountain claims. Should Nevada Zinc complete the purchase of these claims, Bravada Gold will retain a royalty on base and precious metals.

In May of this year, Bravada Gold announced that it received notice that a third-phase drilling program is underway at its Baxter Low-sulfidation gold property in the Walker Lane Gold trend in Nevada. Kinross Gold U.S.A., Inc. plans to drill 8 to 12 reverse-circulation (R.C.) holes for roughly 2,600 meters. Kinross Gold U.S.A. is a wholly-owned subsidiary of Kinross Gold Corp.

The Baxter property comprises 240 unpatented lode claims (approximately 1,940 hectares) in the Walker Lane Gold trend of western Nevada. Bravada Gold previously demonstrated widespread low-sulfidation gold and silver mineralization at surface and in relatively shallow reverse-circulation drill holes at a number of target areas.

Bravada Gold Corp. (BGAVF), closed Friday's trading session at $0.13, up 30.00%, on 101,500 volume with 19 trades. The average volume for the last 60 days is 24,836 and the stock's 52-week low/high is $0.0732/$0.2567.

Digatrade Financial Corp. (DIGAF)

MarketWatch and InvestorsHub reported earlier on Digatrade Financial Corp. (DIGAF), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Digatrade Financial Corp. is an international digital asset exchange and blockchain development services company. It engages in the licensing, development, and branding of a digital exchange trading platform and a peer to peer electronic payment processing network for enabling users to trade fiat and alternative currencies. In essence, DIGATRADE is a Digital Asset, Currency (Bitcoin) Exchange, and Internet Financial Services Company owned and operated by Digatrade Financial Corp.

Established in 2000, the Company lists on the OTC Markets’ OTCQB. It formerly went by the name Bit-X Financial Corporation. It changed its corporate name to Digatrade Financial Corp. in October 2015. Digatrade Financial has its head office in Vancouver, British Columbia.

Currently, Digatrade Financial is developing several new technologies for the Digatrade Core 2.0 Digital Asset Trading Platform. In addition, the Company is seeking more new opportunities and partners for growth as Bitcoin (BTC) continues to increase in value with a market capitalization now in excess of $23.5 Billion.

Digatrade has launched the Digatrade OTC Trade Desk. The new Digatrade Over-the-Counter (OTC) trading service will let KYC verified customers to complete trades outside the online liquidity order book at competitive market prices.

Digatrade Financial provides operational support specializing in web-based digital currency exchange and transaction services for the cryptographic digital currencies. This includes Bitcoin and other alternative digital coins.

The Company provides a user-friendly, secure, and affordable platform to buy and sell Bitcoin and other digital assets. Digatrade provides a 24-hour online platform. This platform provides the automated matching of orders between its registered members.

The proprietary Digatrade trading and matching engine manages high volume, high throughput, and low latency trading. Also, this engine features blended multi-currency settlement in addition to real time FX pricing and risk management fully powered by ANX Technologies. The order engine delivers pre-scan indicative pricing. Users can decide to either fix the quantity of Bitcoins or fix the price paid for every order.

This month, Digatrade Financial announced the listing addition of Ethereum ''ETH'' paired to BTC on the trading platform. This will afford Digatrade customers and shareholders first access to register for the Digafund21 (D21) token release on the already established, safe, and secure Digatrade platform. At present, the Company is now evaluating security protocol to increase crypto-currency pairings, which may include DASH, EOS, BITCOIN CASH, TETHER, MONERO, MERCURY, ZCASH, and NEO, among others.

Digatrade Financial Corp. (DIGAF), closed Friday's trading session at $0.538, up 7.60%, on 443,756 volume with 169 trades. The average volume for the last 60 days is 1,159,824 and the stock's 52-week low/high is $0.021/$1.06.

Rego Payment Architectures, Inc. (RPMT)

Investing, InvestorsHub, and MarketWatch reported on Rego Payment Architectures, Inc. (RPMT), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Rego Payment Architectures, Inc. formerly operated under the name Virtual Piggy, Inc. On March 16, 2017, the Company, creators of the only COPPA compliant technology targeted at providing payment capability for the under 18 market, announced its name change to reflect the progression of the Company into broader payment-related markets. Rego Payment Architectures lists on the OTC Markets Group’s OTCQB.

REGO Payment Architectures, Inc. became an umbrella under which the Intellectual Property (IP) developed becomes available to many different industries beyond the under 18 market. Rego Payment Architectures is headquartered in Palm Beach, Florida.

The Company’s core technology base is established on validated artificial intelligence (AI) techniques. It has extensive capability to adapt to a wide assortment of payment markets and users.

The core technology comprises ReTRO (Real Time Regulatory Oversight), established on advanced AI techniques, a system of reasoning engines, and a Contract Model (CM), which permits the creation of specific boundary conditions for its use.

Rego also has its NOMad (Networks of Meaning ad-vantage). This is an advanced data mining application that monitors people and the things they interact with. Furthermore, the Company has its RSM (REGO Payment Architectures, Secure Financial Messaging) - the payment control system.

REGO Payment Architectures signed a definitive agreement with Be Informed BV, effective July 2017, for the Company’s commercial launch of its unique digital mobile payment system. The terms and conditions allow Rego's COPPA compliant OINK payment platform unlimited use of its developed technology to be available to children and their families for direct mobile payments.

In addition, Rego Payment Architectures and Be Informed entered into three new MOU’s in expectation of the many and diverse expanding markets where this mobile payment technology will be advantageous. The MOU's allow Rego to enter into production agreements under like terms and conditions to its OINK payment platform. The agreements cover the expected welfare benefits, the unbanked and closed loop platforms.

REGO Payment Architectures has its Beta version of the OINK Payment System for Children. OINK (Online Instant Networking Keypad) is a technology that speeds up payments and makes making payments simple and streamlined.

Fundamentally, Rego Payment Architectures is redirecting its efforts to instant Peer to Peer (P2P) transfers employing mobile phones and online systems. The Company’s new business model is an instant revenue producing membership system. It provides Rego Payment Architectures with greater flexibility in fund management. It also provides extra layers of security to protect members’ privacy and their transactions.

Rego Payment Architectures, Inc. (RPMT), closed Friday's trading session at $0.24, up 17.07%, on 124,475 volume with 25 trades. The average volume for the last 60 days is 40,695 and the stock's 52-week low/high is $0.10/$0.44.

Avalon Globocare Corp. (AVCO)

OTC Markets, InvestorsHub, and TradingView reported on Avalon Globocare Corp. (AVCO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Avalon Globocare Corp. provides healthcare services in the U.S. and China. The Company operates via its main platforms: Avalon Cell and Avalon Rehabilitation. Avalon’s management draws on their abundance of experience and extensive networks in the biotechnology industry, health care management, as well as academia. Avalon Globocare is based in Freehold, New Jersey. The Company lists on the OTC Markets’ OTCQB.

Avalon Globocare is a premier healthcare management provider and biotechnology developer. Avalon’s commitment is to integrating and managing worldwide healthcare resources. In addition, Avalon, by way of its subsidiary “Avalon RT9 Properties, LLC”, engages in the acquirement and management of healthcare facilities.

The Company’s “Avalon Cell” platform concentrates on cell-based therapies and technologies. Its focus is in the field of in vitro diagnostics, regenerative medicine, and also cancer immunotherapy. Avalon Cell focuses on transformative and high-impact cell-based bio-technology opportunities in the U.S. and China. It then fast tracks these to clinical development and commercialization internationally.

The “Avalon Rehabilitation” platform is a turnkey, complete suite of rehabilitation services. These services include PT, OT, robotic engineering, cybernectics, and clinical nutrition. Regarding Avalon Globocare’s healthcare facility, it presently includes healthcare property management services, chiefly through acquiring and managing healthcare real estate facilities, stem cell banks, and a CAP-certified laboratory, which will complement the Company’s existing platforms.

Last week, Avalon Globocare announced that its majority-owned subsidiary, GenExosome Technologies, Inc., acquired 100 percent of the outstanding capital stock of Beijing Jieteng (Beijing GenExosome) Biotech Co. Ltd. At the same time, GenExosome entered into and closed an Asset Purchase Agreement with Dr. Yu Zhou, Chief Executive Officer of GenExosome Beijing, whereby GenExosome acquired all assets, including all intellectual property (IP), patents and patent applications held by Dr. Zhou regarding the business of researching, developing, and commercializing exosome technologies.

This week, Avalon Globocare announced that it appointed former Congressman, Mr. Billy Tauzin, to the Company’s Board of Directors. Congressman Tauzin has a long and distinguished 36-year elective career. It culminated in chairing the Energy and Commerce Committee (ECC) in the U.S. House of Representatives. The ECC supervises food and drug safety, public health and research, telecommunications, consumer protection, environmental quality, energy policy, and interstate and foreign commerce among others.

Avalon Globocare Corp. (AVCO), closed Friday's trading session at $2.50, up 6.38%, on 1,000 volume with 1 trade. The average volume for the last 60 days is 1,103 and the stock's 52-week low/high is $0.51/$5.00.

CurAegis Technologies, Inc. (CRGS)

OTC Markets and InvestorsHub reported on CurAegis Technologies, Inc. (CRGS), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, CurAegis Technologies, Inc. develops and markets advanced technologies in the areas of power, safety, and wellness. The Company consists of two independent divisions - its CURA Division and its Aegis Division. CurAegis is presently focusing on commercialization strategies in varied technologies. These include the CURA system, which includes the myCadian™ watch that measures degradation of alertness and sleep attributes; the Z-Coach e-learning education and training tool, and the Aegis hydraulic pump. CurAegis Technologies is headquartered in Rochester, New York.

The CURA System consists of hardware and software that measures manifold metrics to establish that a person's ability to perform a task or job appears to be degrading. The CURA division is developing a proprietary technology and family of products designed to measure the decrease in a person’s alertness and to train persons on how to improve alertness levels.

The CURA™ system and the myCadian™ watch enable the user and third parties to anticipate and prevent undesired or disastrous situations caused by the degradation of alertness. CurAegis Technologies completed its validation studies of the CURA System at the University of Colorado at Boulder and the University of Rochester Medical Center. The Company earlier said that it can now state that it can predict a person’s fatigue level, at close to laboratory accuracy, in real-time.

The Z-Coach e-learning tool was acquired by CurAegis Technologies in September 2015. The first of six Z-Coach e-learning modules, Z-Coach Aviation, was designed for aviation professionals. If the CURA (Circadian User Risk Assessment) software detects an issue, Z-Coach creates a back-end solution required to induce change and improve behavior. The program is broken down into two parts: Z-Coach Education and Z-Coach Intervention.

Moreover, the Company’s Aegis hydraulic pump (Aegis Division) is a unique hydraulic design. Its objective is to deliver better efficiencies in a package that is smaller and lighter than contemporary technologies.

Concerning the Aegis Division’s Aegis Pump and Motor, it has eliminated the rotating piston group (the cylinders are stationary). This makes the pump very strong and easy to manufacture. The Company’s patented valving has been integrated to increase efficiencies at peak and off peak operation.

The Company’s plan is to license its technology to major manufacturers. It may consider an exclusive licensing agreement for a period of time if it believes that it is the best way to reach the original equipment manufacturer (OEM) and after-market customers.

Concerning the CURA System, it now works with iOS and Android phones. The Company has aligned the communications between its watch, the smart phone and its cloud.

The CURA System will make an individual aware of the importance of sleep in their daily life. It will show one how to easily change their behavior to make their life safer, healthier, and longer. In addition, it gives a person accurate and relevant real-time information about their current and long-term sleep and fatigue health.

CurAegis Technologies, Inc. (CRGS), closed Friday's trading session at $0.30, up 19.00%, on 21,948 volume with 9 trades. The average volume for the last 60 days is 22,466 and the stock's 52-week low/high is $0.246/$1.91.

Vycor Medical, Inc. (VYCO)

PennyStockScholar, FeedBlitz, OTCtipReporter, and Wall Street Resources reported earlier on Vycor Medical, Inc. (VYCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Vycor Medical, Inc. is a provider of distinct and first-class surgical and therapeutic solutions. The Company operates two business units - Vycor Medical and NovaVision. Both of these business units adopt a minimally or non-invasive approach. Vycor Medical has U.S. Food and Drug Administration (FDA) 510(k) clearance for brain and spine surgeries and regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea, Japan, Russia, and Taiwan. Vycor Medical is based in Boca Raton, Florida.

The Company’s NovaVision provides non-invasive, computer-based rehabilitation targeted at a substantial and largely un-addressed market of people who have lost their sight because of stroke or brain injury. The NovaVision business unit develops and provides science-driven neurostimulation therapy and other medical technologies. This helps improve and partially restore sight in patients with neurological vision impairments.

Vycor Medical’s ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices. These have the potential for quicker, safer, and also more economical brain surgeries, as well as faster patient discharge.

The design of VBAS is to optimize neurosurgical site access and reduce patient risk. In addition, the design of VBAS is to expedite recovery and add tangible value to the professional medical community.

The Company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (TBI), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the United States targeted at the restoration of vision for neurologically induced vision loss.

Vycor Medical has developed NeuroEyeCoach™. This is a therapy that is highly complementary to VRT™. NeuroEyeCoach™ is a compensation therapy registered in the United States as a Class I 510(k) exempt device. The design of NeuroEyeCoach is to improve a patient's ability to scan their environment more efficiently. NeuroEyeCoach is NovaVision's eye movement compensation therapy for patients who have suffered a cerebral visual field disorder due to a stroke or brain injury.

In August, Vycor Medical reported financial results for the three and six months ended June 30, 2017. The Company’s Revenues for the six months ended June 30, 2017 were $736,000 versus $779,000 for the same period the year prior. Cash Operating Loss was $235,000, versus $329,000 for the same period in 2016. This represents a reduction of 29 percent. Operating Loss was $654,000, versus $806,000. This represents a reduction of 19 percent.

During the period, the US patent office (USPTO) issued/allowed four patents. These are all directed to the integration of neuro-navigation systems with Vycor Medical's VBAS retractor system.

The patents complement and strengthen the Company’s existing patent portfolio. This is especially in relation to Vycor’s continuing emphasis to more fully integrate its VBAS product range with neuro-navigation systems without sacrificing the surgeon's ability to visually inspect the surrounding tissue as the devices undergo insertion.

Vycor Medical, Inc. (VYCO), closed Friday's trading session at $0.5099, up 13.31%, on 9,300 volume with 12 trades. The average volume for the last 60 days is 5,340 and the stock's 52-week low/high is $0.122/$0.546.

Creative Medical Technology Holdings, Inc. (CELZ)

OTC Markets and MarketWatch reported on Creative Medical Technology Holdings, Inc. (CELZ), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Creative Medical Technology Holdings, Inc. (CMT) is a clinical stage stem cell company. Its focus is on Urology and Neurology utilizing stem cell treatments. CMT and its affiliate company, Creative Medical Health, Inc., have concentrated on regenerative medical solutions for unmet Urological and Neurological needs since 2011. The Company has a patent portfolio covering all treatments. CMT has its headquarters in Phoenix, Arizona.

The Company (via its own research and also collaborations with leading academic institutions) has acquired a pioneering stem cell (Amniostem), and developed proprietary protocols. It has also built an extensive intellectual property (IP) portfolio, developed complete treatment offerings for erectile dysfunction (ED), and launched a 40-patient trial for ED at UCLA. Moreover, CMT is making advances for treating stroke employing its newly acquired amniotic fluid-based stem cell.

Amniostem is Amniotic fluid derived stem cell. The Amniostem patent covers means to isolate, grow, and use amniotic fluid derived stem cells in a scalable and commercializable way. Amniostem therapy is a practical protocol for producing therapeutic quality stem cells starting from a small (1-5 ml) amniocentesis sample. Amniostem cells do not require matching with the recipient, as one size fits all.

CMT has its StemSpine™ initiative. This is a treatment designed to reverse the affects of atherosclerosis, which is the underlying disease that causes disc degeneration. CMT’s solutions include Caverstem™ for Erectile Dysfunction (ED).

The Company has an exclusive rights agreement with UCLA for US patent application # 14/508763, encompassing the use of stem cells for the treatment of male infertility. Additionally, CMT has filed US patent application number #62319753, covering the treatment of female sexual dysfunction utilizing stem cell and progenitor cell populations.

CMT announced in July 2017 preclinical data showing exosomes harvested from its patented Amniostem amniotic fluid stem cell, selectively inhibit growth of glioma brain cancer cells.  Exosomes are nanoparticles generated by a variety of cells that are critically involved in intercellular communication. CMT earlier filed patents on the use of Amniostem derived exosomes for the treatment of stroke.

Last month, CMT announced the filing of a patent application utilizing a combination of a Food and Drug Administration (FDA) approved drug together with the patient's own bone marrow derived stem cells for the treatment of stroke. The patent, entitled "Autologous Bone Marrow Mononuclear Cells as a Substrate for Enhancement of Neuroregenerative Therapy", encompasses the use of the patient's bone marrow stem cells, together with an FDA approved drug, to stimulate the naturally occurring regenerative processes after certain kinds of strokes.

At present, CMT has two issued patents using the patient's own bone marrow stem cells covering disc regeneration #9,598,673, and erectile dysfunction #8,372,797. CMT recently reported completion of enrolment in its clinical trial for erectile dysfunction.

In addition, last month, CMT announced completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem™ procedure. The trial was sponsored by CMT.

The trial was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval. Furthermore, an independent medical safety monitor was appointed to review the patient data for safety and feasibility of administering bone marrow derived stem cells into patients with erectile dysfunction.

Creative Medical Technology Holdings, Inc. (CELZ), closed Friday's trading session at $0.0135, up 17.39%, on 125,265 volume with 11 trades. The average volume for the last 60 days is 153,221 and the stock's 52-week low/high is $0.01/$0.70.

graphic

The QualityStocks
Company Corner

graphic
graphic

Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.7195, off by 6.28%, on 787,007 volume with 612 trades. The stock’s average daily volume over the past 60 days is 193,220 and its 52-week low/high is $0.2032/$0.881.

Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), announces that it has completed a prestudy visit of the Fundación de Investigación (“FDI”) facilities in San Juan, Puerto Rico.  This will be the site where the Company’s research arm, Cannevert Therapeutics Ltd. ("CTL") will be conducting its first human study of CTL-X, a cannabis strain targeting pain management.

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Veritas and Cannevert Complete Prestudy Visit of the Puerto Rico Clinical Trial Facility

Veritas Pharma Subsidiary Receives Health Canada Dealer Licence

Veritas Hires Medical Director to Advise Physicians & Regulators on the Application of Cannevert’s Experimental Results with Cannabis to Clinical Practice & Public Policy

Grey Cloak Tech, Inc. (GRCK)

The QualityStocks Daily Newsletter would like to spotlight Grey Cloak Tech, Inc. (GRCK). Today, Grey Cloak Tech, Inc. closed trading at $0.0066, up 24.53%, on 39,302,147 volume with 431 trades. The stock’s average daily volume over the past 60 days is 9,228,996 and its 52-week low/high is $0.0027/$0.1499.

Grey Cloak Tech, Inc. (OTCQB: GRCK), a Las Vegas, Nevada-based company, aims to expand into the rapidly growing cannabinoid (CBD) market through the pending acquisition of Eqova Life Sciences, which focuses on providing a full spectrum line of clinical-grade hemp oil (CBD) products to the medical practitioner market. Eqova Life Sciences, based in Denver, Colorado, develops its own high quality, branded product line of hemp oil health products, with the offer of producing private labels to qualified partners.

Eqova Life Sciences recently exhibited the company's CBD products at the Integrative Medicine Summit in Denver, Colorado, which was attended by over 200 medical professionals. As part of the exhibition, Eqova Life Sciences also debuted its new CannaBio Salve, an innovative topical salve infused with several aromatic natural oils. The company's formulations combine the scientifically-validated, powerful benefits of cannabinoids in standardized products which are then distributed to patients under the care of qualified health practitioners. All Eqova products are carefully researched and go through rigorous third-party testing before and after marketing, providing the security of a clinical-grade product made in cGMP Compliant Labs located in the United States.

According to The Hemp Business Journal, the CBD products marketplace is projected to grow 700 percent by 2020 with annual sales reaching $2.1 billion. The purchase of Eqova Life Sciences would be a natural fit for the company, which has been looking for a way to build shareholder value by adding acquisitions from the rapidly growing CBD sector. Grey Cloak Tech believes medical practitioners seeking high-quality CBD products represent a vastly underserved market. To date, no other hemp oil company has exclusively focused on providing clinical-grade, full-spectrum hemp oil products to this important segment of the medical community.

Grey Cloak Tech also develops advanced software to overcome costly digital threats, most commonly known as online fraud. Grey Cloak Tech leads the industry with continuous development of the most comprehensive and effective weapons against online security threats. The company's proprietary digital advertising fraud detection software, Fraudlytic, provides a cloud-based, secure platform that monitors Internet traffic in real time, blocking malicious and false clicks, while allowing real consumers to view offers and make purchases. Disclaimer

Grey Cloak Tech, Inc. Blog

Grey Cloak Tech, Inc. News:

Grey Cloak Tech Announces Hiring of Stephen Goldberg as New Chief Marketing Officer for CBD.co

Grey Cloak Tech, Inc. Announces Purchase of CBD.co Domain and Plans to Build a CBD Marketplace

Grey Cloak Tech, Inc. to Introduce CannaBio Salve at MJBizCon in Las Vegas

EVIO, Inc. (EVIO)

The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO). Today, EVIO, Inc. closed trading at $1.36, up 18.26%, on 241,865 volume with 416 trades. The stock’s average daily volume over the past 60 days is 55,368, and its 52-week low/high is $0.47/$3.20.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation's leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation's cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation's leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today's fastest growing industry. Disclaimer

EVIO, Inc. Company Blog

EVIO, Inc. News:

EVIO Labs Colorado Licensee Announces ISO 17025 Accreditation

EVIO Inc. to Purchase Licensed Cannabis Laboratory in Northern California

EVIO Inc. Granted Expanded Accreditation to Test for Pesticides and Residual Solvents

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.69, up 2.42%, on 323,505 volume with 460 trades. The stock’s average daily volume over the past 60 days is 388,199 and its 52-week low/high is $0.27/$2.13.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) and its Revolutionary Technology are Ready for the Cannabis Industry

Uptick Newswire “Stock Day” Interviews CEO of Lexaria on Cannabis Related Products and Recent Bioscience Patents

Lexaria Bioscience Receives U.S. Patent Award for its DehydraTECH(tm) Delivery of THC, NSAIDs, Nicotine and Vitamins

Greenkraft, Inc. (GKIT)

The QualityStocks Daily Newsletter would like to spotlight Greenkraft, Inc. (GKIT). Today, Greenkraft, Inc. closed trading at $0.09, off by 18.18%, on 3,025 volume with 2 trades. The stock’s average daily volume over the past 60 days is 6,731 and its 52-week low/high is $0.02/$0.20.

Greenkraft, Inc. (GKIT) is a nationally recognized company specializing in the production of alternative fuel automotive products, including engines and commercial trucks. Located in Santa Ana, California, the company's mission is to provide clean, green, energy efficient automotive products that have a price advantage coupled with unparalleled American performance. Established in 2008, Greenkraft, Inc. serves the commercial truck market powered by the alternative fuels CNG and LPG in classes 4, 5, 6 and 7.

Greenkraft's new line of trucks, known as the G3 and G4, will accommodate weights of 26,000 lbs. and 33,000 lbs., respectively. George Gemayel, CEO of Greenkraft, Inc., said the demand for larger trucks that run on alternative fuels continues to increase.

"Greenkraft is going to revolutionize the trucking industry with these new 26,000 and 33,000 lbs. trucks that run on CNG and PROPANE fuel," Gemayel states in a press release. "The only way we can meet increased demand for Greenkraft products is to expand our current factory. This expansion is one of many factors that will substantially increase the Company's revenue in 2017."

Greenkraft produces a cab forward design for its commercial trucks, which allows the passenger area to be much larger than in other similar sized vehicles. Several tank capacity options exist, making it easy to select the most efficient model for a client's specific needs. Greenkraft is one of the only companies in the world to offer a refrigeration option with an alternative fuel truck – an essential, must-have option for many businesses.

Greenkraft trucks, considered among the best performing in the heavy-duty market, are used in a variety of industries and in some of the nation's largest cities. The company also offers a line of trucks designed to run with a package from Allison Transmission Holdings, Inc. (NYSE: ALSN), which gives clients the option of purchasing a fully automatic transmission vehicle. This option expands the size of the driver pool since fully automatic shifting reduces driver fatigue, contributes to solving the issue of driver retention, and it is easy to use.

CNG and LPG conversion systems made by Greenkraft are available for several major automobile brands including Ford, GM and Isuzu/GM. Installation, service, parts and warranty are all available through Greenkraft facilities and its partners. Disclaimer

Greenkraft, Inc. Blog

Greenkraft, Inc. News:

Greenkraft, Inc. (GKIT) Sees Jump in Sales for its Commercial Truck Line

Greenkraft, Inc. (OTCQB: GKIT) Signs Supply Contracts for its Alternative Fuel Commercial Trucks, Rising to Meet Industry Demand

Greenkraft, Inc.'s (GKIT) Alternative Fuel Engine Awarded Certification for Exceeding California's Clean Air Act Standards

RJD Green Inc. (RJDG)

The QualityStocks Daily Newsletter would like to spotlight RJD Green Inc. (RJDG). Today, RJD Green Inc. closed trading at $0.00899, off by 0.11%, on 426,611 volume with 8 trades. The stock’s average daily volume over the past 60 days is 1,147,951, and its 52-week low/high is $0.004/$0.029.

RJD Green Inc. (RJDG) is a holding company with a focus on acquiring and managing assets and companies in three divisions. These initial high-growth enterprise opportunities offer diversity in separate recession resistant markets. The division holdings include:

  • RJD Green Healthcare Services – provides services to reduce cost and enhance management and operational capabilities in the healthcare sector.
  • Earthlinc Environmental Services – provides green environmental services and technologies.
  • Silex Holdings – acquires specialty construction and industrial manufacturing assets.

RJD Green Healthcare Services, through its wholly owned subsidiary IOSOFT Inc., provides proprietary software and IT support for medical billing, healthcare claims adjudication, and electronic payments between healthcare payers and providers. IOSOFT's unique payment technologies and services or software can be integrated with existing systems of healthcare payers such as Blue Cross, Aetna, CIGNA and others. IOSOFT provides targeted offerings for healthcare providers, provider networks, physicians and hospitals, and clearinghouse companies.

Earthlinc Environmental Solutions was formed to bring forward green-applied technologies and offer environmental services with a focus on North America. The division's first acquisition, Animal Waste Management, is launching operations of a patented, fully developed technology for processing waste produced on commercial poultry and hog farms. Development of this technology was supported by the University of Arkansas and the Missouri Department of Natural Resources. This important technology improves the farm's productivity and is competitively priced with the current expense of handling waste removal at these sites.

The company's third division – Silex Holdings Inc. – was formed to acquire and manage high-growth assets and business enterprises in the industrial and construction specialty services sectors. With its first acquisition of Silex Interiors, a manufacturer, distributor and installer of counter tops, cabinets and related kitchen and bath products, the division is poised to expand into major national markets through internal expansion, acquisition and franchising. The company is modeled to operate a minimum of four corporately owned locations with 12 to 18 franchise locations nationwide.

RJD Green seeks to participate as owners, partners or in joint ventures in a wide range of business enterprises. The company's goal of creating a successful, enjoyable business enterprise for its company team and staff, along with its business partners and investors, is paired with the goal of maximizing the business potential of the enterprise by enhancing profits and the quality of the company. Disclaimer

RJD Green Inc. Company Blog

RJD Green Inc. News:

RJD Green, Inc. Updates Progression of Animal Waste Management and 2017 10K Filing

RJD Green Inc. Appoints Director

RJD Green Inc. Subsidiary, IOSOFT, Discusses Contracts Procured and Revenue Expectations

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.10, off by 0.50%, on 14,138,369 volume with 872 trades. The stock’s average daily volume over the past 60 days is 10,487,809, and its 52-week low/high is $0.01/$0.415.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsAudio Covers SinglePoint’s Release on Calendar Year 2016 Audit, Advances Towards Up-Listing

SinglePoint Completes Calendar Year 2016 Audit, Advances Toward Up-Listing

CannabisNewsWire Announces Publication Discussing Innovative Solutions in the Surging Cryptocurrency Market

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

StockMarketWatch
(XNY) +59.20%

2.

QualityStocks
(BGAVF) +30.00%

3.

NetworkNewsWire
(GRCK) +24.53%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251